证券代码：002020 证券简称：京新药业 公告编号：2025054 浙江京新药业股份有限公司董事会 2025 年 10 月 11 日 职工代表董事简介 浙江京新药业股份有限公司（以下简称"公司"）第八届董事会任期即将届 满，公司根据《公司法》《深圳证券交易所股票上市规则》《深圳证券交易所上 市公司自律监管指引第 1 号——主板上市公司规范运作》《公司章程》等法律法 规、规范性文件的有关规定，开展董事会换届选举工作。 公司于 2025 年 10 月 10 日召开第八届三次职工（会员）代表大会，经与会 职工代表审议，同意选举徐小军先生为公司第九届董事会职工代表董事（简历详 见附件）。徐小军先生将与公司 2025 年第一次临时股东大会选举产生的第九届 董事会非独立董事和独立董事共同组成第九届董事会，任期三年，与第九届董事 会任期一致。 第九届董事会职工代表董事徐小军先生符合《公司法》《公司章程》等法律 法规、规范性文件关于董事任职的资格和条件。本次换届选举完成后，第九届董 事会中兼任公司高级管理人员以及由职工代表担任的董事人数总计未超过公司 董事总数的二分之一，符合相关法律法规的要求。 特此公告。 浙江京新药业股 ...

证券代码：002020 证券简称：京新药业 公告编号：2025055 浙江京新药业股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 重要提示： 1、本次股东大会无否决提案的情况； 2、本次股东大会以现场投票和网络投票相结合的方式召开。 一、会议召开情况 1、本次股东大会的召开时间 现场会议时间：2025 年 10 月 10 日 9:30 起。 网络投票：通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 10 月 10 日 9:15—9:25,9:30—11:30 和 13:00—15:00；通过深圳证券交易 所互联网投票系统进行网络投票的具体时间为 2025 年 10 月 10 日 9:15 至 15:00 的任意时间。 2、现场会议地点：浙江省新昌县羽林街道新昌大道东路 800 号本公司行政 楼一楼会议室。 3、会议召开方式：本次会议采取现场投票与网络投票相结合的方式。本次 股东大会通过深圳证券交易所交易系统和互联网投票系统向公司股东提供网络 形式的投票平台，股东可以在网络投票时间内通过上述系统 ...

证券代码：002020 证券简称：京新药业 公告编号：2025056 浙江京新药业股份有限公司 第九届董事会第一次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记载、 误导性陈述或者重大遗漏。 浙江京新药业股份有限公司（以下简称"公司"）第九届董事会第一次 会议通知于 2025 年 9 月 26 日以电子邮件形式发出，会议于 2025 年 10 月 10 日在公司行政楼一楼会议室召开。会议应到董事 9 名，实到董事 9 名，公司 高级管理人员列席了会议，会议召开符合《公司法》及《公司章程》的有关 规定。会议由董事长吕钢先生主持，会议经表决形成如下决议： 一、逐项审议通过了《关于选举第九届董事会董事长和副董事长的议案》。 1、以 9 票同意、0 票反对和 0 票弃权的表决结果，同意选举吕钢先生为 公司第九届董事会董事长，任期三年，自 2025 年 10 月 10 日起至 2028 年 10 月 9 日止。 2、以 9 票同意、0 票反对和 0 票弃权的表决结果，同意选举王能能先生 为公司第九届董事会副董事长，任期三年，自 2025 年 10 月 10 日起至 2028 年 10 月 ...

Company Overview - Jingxin Pharmaceutical (SZ 002020) announced the first meeting of its ninth board of directors on October 10, 2025, to review the proposal for the election of committee members [1] - As of the report, Jingxin Pharmaceutical has a market capitalization of 16.9 billion yuan [1] Revenue Composition - For the first half of 2025, the revenue composition of Jingxin Pharmaceutical is as follows: finished drugs account for 58.28%, raw materials account for 22.44%, medical devices account for 17.32%, and other businesses account for 1.95% [1]

上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于浙江京新药业股份有限公司 2025 年第一次临时股东大会的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于浙江京新药业股份有限公司 2025 年第一次临时股东大会的 法律意见书 致：浙江京新药业股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受浙江京新药业股份有限公 司（以下简称"公司"或"京新药业"）委托，就公司召开 2025 年第一次临时股东 大会（以下简称"本次股东大会"）的有关事宜，根据《中华人民共和国公司法》 （以下简称《公司法》）、《上市公司股东会规则》等法律、法规、规章和其他规 范性文件以及《浙江京新药业股份有限公司章程》（以下简称《公司章程》）的有 关规定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉 ...

Core Viewpoint - The Chinese insomnia medication market is poised for rapid growth and transformation, driven by increasing awareness of sleep disorders and government initiatives to enhance sleep health services [2][3][12]. Group 1: Market Overview - Approximately 1/4 of the Chinese population suffers from sleep deprivation, with nearly 40% experiencing nighttime awakenings, indicating a significant market potential for insomnia treatments [3]. - The insomnia medication market in China is projected to reach 350 billion RMB by 2025, reflecting a growing demand for effective sleep aids [6][15]. - The recent approval of new insomnia medications, such as Fazamorexant and Daliresp, marks a shift in the market, with companies like Yangtze River Pharmaceutical Group and Xiansheng Pharmaceutical leading the charge [8][9]. Group 2: Industry Challenges - The Chinese insomnia medication market has faced a 16-year gap in new drug approvals, primarily due to stringent regulatory policies governing psychotropic medications [12]. - Traditional insomnia medications often come with significant side effects, leading to a dilemma for patients seeking effective treatment options [13][14]. - There is a lack of specialized sleep medicine departments in hospitals, complicating the diagnosis and treatment process for insomnia patients [14]. Group 3: Opportunities for Innovation - The increasing prevalence of insomnia, particularly among the aging population, presents a substantial opportunity for pharmaceutical companies to develop innovative treatments [15]. - Advances in technology, such as AI-assisted drug development and digital therapies, are expected to shorten research timelines and expand treatment options [15]. - The government's "Healthy China 2030" initiative aims to integrate insomnia interventions into primary healthcare services, potentially increasing market penetration for insomnia medications [15].

浙江京新药业股份有限公司 关于股份回购进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 证券代码：002020 证券简称：京新药业 公告编号：2025053 截至 2025 年 9 月 30 日，公司通过股份回购专用证券账户以集中竞价方式回 购公司股份 4,727.1295 万股，占公司目前总股本的 5.49%，购买股份最高成交 价为 14.41 元/股，购买股份最低成交价为 11.86 元/股，成交总金额为 60,872.22 万元（不含交易费用）。 本次回购股份资金来源为公司自有资金，回购价格未超过 14.47 元/股（含）。 本次回购符合相关法律法规的要求，符合既定的回购方案。 三、其他情况说明 公司回购股份的时间、回购股份数量及集中竞价交易的委托时间段均符合 《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》第十七条、十八 条的相关规定。 1、公司未在下列期间内回购股份： （1）自可能对本公司股票交易价格产生重大影响的重大事项发生之日或者 在决策过程中，至依法披露之日内； 一、回购股份方案的基本情况 浙江京新药业股份有限公司(以下简称"公 ...

Group 1 - The company, Jingxin Pharmaceutical, announced a share buyback of approximately 47.27 million shares, representing 5.49% of its total share capital, with a total expenditure of about 609 million yuan [1] - The highest and lowest purchase prices during the buyback were 14.41 yuan and 11.86 yuan per share, respectively [1] - As of the report, Jingxin Pharmaceutical's market capitalization stands at 17.5 billion yuan [1] Group 2 - For the first half of 2025, the revenue composition of Jingxin Pharmaceutical is as follows: finished drugs account for 58.28%, raw materials account for 22.44%, medical devices account for 17.32%, and other businesses account for 1.95% [1]

Core Viewpoint - The National Healthcare Security Administration has announced the 11th batch of centralized drug procurement, which will take place on October 21, covering 55 varieties and 162 specifications, including key areas such as antiviral and kidney disease treatment drugs [1][2]. Group 1: Drug Procurement Policy - The 11th batch of centralized procurement aims to stabilize clinical practices, ensure quality, prevent collusion, and avoid excessive competition [1]. - The new procurement rules will optimize price control mechanisms to prevent companies from underbidding, which previously led to unsustainable low prices [1][4]. - The focus on high-value consumables and medical devices is expected to benefit companies with strong cost advantages and product quality, particularly in major categories like cardiovascular and anti-infection drugs [4][5]. Group 2: Market Opportunities and Challenges - The centralized procurement policy presents both opportunities and challenges for pharmaceutical companies, prompting some generic drug firms to shift towards a combination of generics and innovation [2][5]. - The "anti-involution" trend in the procurement sector is expected to primarily benefit high-value consumables, which have been adversely affected by previous procurement rounds [2][4]. Group 3: Long-term Investment Perspective - Investors are advised to adopt a long-term perspective, as some innovative drug stocks are currently overvalued following previous market enthusiasm [3][9]. - The ongoing improvement of procurement policies is seen as a catalyst for the healthy development of the pharmaceutical industry, favoring large innovative drug companies with strong R&D capabilities [5][9]. Group 4: Company Performance and Projections - Companies like Kelun Pharmaceutical, Jingxin Pharmaceutical, and Fosun Pharma are highlighted for their strong R&D pipelines and potential for growth, with Kelun having over 30 projects focused on oncology [6][7]. - Fosun Pharma has made significant progress in its innovative transformation, with multiple products showing promising clinical trial results [6][8]. - China National Pharmaceutical Group is expected to have nearly 20 innovative products approved in the next three years, with several projected to exceed sales of 2 billion RMB [8].

Group 1 - The chemical pharmaceutical sector increased by 1.63% on September 30, with Mengke Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3882.78, up 0.52%, while the Shenzhen Component Index closed at 13526.51, up 0.35% [1] - Notable gainers in the chemical pharmaceutical sector included Mengke Pharmaceutical, which rose by 8.45% to a closing price of 9.11, and Yong'an Pharmaceutical, which increased by 6.92% to 18.08 [1] Group 2 - The chemical pharmaceutical sector saw a net inflow of 256 million yuan from main funds, while retail investors experienced a net outflow of 320 million yuan [2] - Key stocks with significant main fund inflows included Heng Rui Pharmaceutical with 37.4 million yuan and Yong'an Pharmaceutical with 134 million yuan [3] - Conversely, stocks like ST Suwu and ST Fuhua experienced declines of 5.00% and 4.97%, respectively, indicating a mixed performance within the sector [2]